- AVF Academy
- Biomarkers to Predict Thromboembolic Pulmonary Hypertension and Refine Patient Selection for Intervention
Biomarkers to Predict Thromboembolic Pulmonary Hypertension and Refine Patient Selection for Intervention
Elizabeth Andraska, MD, MScAssistant Professor of Vascular Surgery, University of Pittsburgh
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but debilitating complication following acute pulmonary embolism (PE). CTEPH is characterized by persistent functional impairments and resting pulmonary hypertension following PE. The condition is associated with significant morbidity and impaired quality of life, positioning early risk stratification and diagnosis as a central objective for those studying CTEPH. While current biomarkers such as pro-BNP, troponin, and lactate help to stratify the acute PE patient into severity categories and identify those at risk for acute clinical decompensation, they are not as helpful at identifying those who will develop chronic complications of PE. Further, a biomarker that predicts CTEPH may help with clinical decision making to help determine which patients should be treated more aggressively with advanced catheter-based therapies.
Mechanistically, CTEPH is thought to arise from the failure of thrombus to completely resolve, which results in localized inflammation and fibrotic remodeling of the pulmonary arteries, chronic right heart strain, and abnormal microvascular overgrowth, ultimately resulting in higher arterial resistance. Collectively, these processes increase pulmonary vascular resistance and drive the transition from acute thromboembolic disease to a chronic obstructive vasculopathy.
Efforts to translate this pathophysiology into clinically applicable biomarkers have started to focus on mediators of cardiopulmonary inflammation and the thromboinflammatory axis. Although several biomarkers demonstrate statistically significant associations with CTEPH, none have been shown to function as a stand-alone diagnostic marker, and none have been used to guide interventional decision making. Given the diagnostic and mechanistic complexity of CTEPH, it is unlikely that a single biomarker will be sufficient to reliably predict disease progression. Rather, current findings may serve as a foundation for a more multimodal, precision- medicine-based approach to diagnosis of CTEPH following PE. If we are ultimately able to use biomarkers to identify patients at most risk for CTEPH, we may be able to more confidently and aggressively treat those patients with advanced catheter-based therapies to improve long term outcomes.





